Jim Simons Ngm Biopharmaceuticals Inc Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.17 - $1.92 $170,342 - $279,536	-145,592 Reduced 19.24%	611,300 $972,000
Q4 2023 Feb 13, 2024	BUY	$0.6 - $1.31 $140,739 - $307,280	234,565 Added 44.91%	756,892 $650,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $283,213 - $908,979	269,727 Added 106.78%	522,327 $559,000
Q2 2023 Aug 11, 2023	SELL	$2.44 - $4.53 $187,636 - $348,357	-76,900 Reduced 23.34%	252,600 $654,000
Q1 2023 May 12, 2023	SELL	$3.72 - $5.4 $52,080 - $75,600	-14,000 Reduced 4.08%	329,500 $1.34 Million
Q4 2022 Feb 13, 2023	BUY	$3.41 - $12.93 $236,313 - $896,049	69,300 Added 25.27%	343,500 $1.72 Million
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $807,875 - $1.13 Million	-64,168 Reduced 18.96%	274,200 $3.59 Million
Q2 2022 Aug 12, 2022	BUY	$10.58 - $17.5 $1.93 Million - $3.2 Million	182,668 Added 117.32%	338,368 $4.34 Million
Q1 2022 May 13, 2022	BUY	$13.81 - $18.6 $1.12 Million - $1.51 Million	81,000 Added 108.43%	155,700 $2.37 Million
Q4 2021 Feb 11, 2022	BUY	$17.26 - $22.02 $1.06 Million - $1.35 Million	61,400 Added 461.65%	74,700 $1.32 Million
Q3 2021 Nov 12, 2021	BUY	$20.15 - $26.19 $267,995 - $348,327	13,300 New	13,300 $280,000
Q4 2020 Feb 10, 2021	SELL	$16.21 - $31.44 $1.33 Million - $2.58 Million	-82,200 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$15.59 - $19.97 $1.35 Million - $1.73 Million	-86,800 Reduced 51.36%	82,200 $1.31 Million
Q2 2020 Aug 13, 2020	BUY	$11.97 - $23.47 $238,203 - $467,053	19,900 Added 13.35%	169,000 $3.34 Million
Q1 2020 May 14, 2020	BUY	$10.0 - $19.51 $1.49 Million - $2.91 Million	149,100 New	149,100 $1.84 Million

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account